Antibody/ Cell Line Development

Our Services

    • Biopanning and isolation of antibody and antibody fragments using both solid and liquid phase panning techniques

    • Sequence recovery (NGS/Sanger sequencing)

    • High purity antibody isolation from expression systems

    • Purification of recombinant protein for functional screening

    • High throughput screening of B-cell repertoires

    • Live-cell phenotypic screening of protein-producing cells

    • Rapid identification of high-binders

    • Screening of engineered libraries

    • Assay development and optimisation to select lead candidate molecules

    • Functional validation in in vitro assays i.e.- binding, internalisation, target-specific assays

Capabilities

Through partnering with the FMI, gain access to the necessary expertise and infrastructure to successfully advance antibody development program.

Key FMI capabilities include: 

  • Phage display discovery technology 

  • Cell line development, expedited by state-of-the-art Cyto-Mine® Chroma single cell analysis platform 

  • Antibody expression, purification and sequencing, including both nucleotide and mass spectrometry-based amino acid profiling 

  • In vitro/vivo characterisation of antibody binding and functionality, with option to obtain clinical samples from NI Biobank 

  • Refinement of target patient cohort through engagement with FMI bioinformatics hub 

Team

Prof Chris Scott

Founder/Academic Lead

Antibody development

Dr Michael Johnston

Research Fellow

Antibody development/ phage display

Dr. Dessi Malinova

Academic Lead

B-cell cloning/ immunology

Dr Peter Smyth

Research Fellow

Antibody development/ phage display

Dr Michelle Greene

Senior Research Fellow

Antibody development/ phage display

Dr Úna Herron

Research Fellow

Antibody development/ phage display

Our technology